- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06716463
Previsão de falha do suporte ventilatório não invasivo usando monitoramento não invasivo em pacientes não intubados com insuficiência respiratória hipoxêmica aguda ou falha pós-extubação. o estudo PREVISION (PREVISION)
Predição de falha do suporte ventilatório não invasivo usando monitoramento não invasivo em pacientes não intubados com insuficiência respiratória hipoxêmica aguda ou falha pós-extubação: o estudo PREVISION
The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).
The main question, it aims to answer is:
Does abnormal regional ventilation could predict HFNC or NIV failure?
Visão geral do estudo
Status
Descrição detalhada
This is a single-center, prospective, physiological study.
The study will enroll patient who has used either HFNC or NIV for the indications of 1. to prevent worsening acute hypoxemic respiratory failure or 2. to prevent reintubation. Once being confirmed to meet the inclusion criteria, the research team will apply the electrical impedance tomography (EIT) on the patient and start recording for 5-10 minutes as well as perform diaphragm and parasternal intercostal muscle ultrasound when the patient is using HFNC or NIV. The current HFNC or NIV setting, some lung mechanic's parameters (e.g. rapid shallow breathing trial (RSBI), negative airway pressure generated during the first 100 milisecond (P0.1), end-expiratory occlusion pressure(ΔPocc) derived from NIV machine), patient's characteristic, dyspnea scores (intensive care respiratory distress observation scale, IC-RDOS; work of breathing scale; self-report of dyspnea visual analog scale, D-VAS), ICU and hospital length of stay will be also collected.
The investigator will use EIT to visualize where air goes in the patient's lung and inspiratory muscle ultrasonography (diaphragm and parasternal intercostal muscle) to visualize the muscle activities when using HFNC or NIV. EIT is a measurement often used in the ICU since it allows easy visualization and is a non-invasive technique. The sensors measure electrical current changes during inspiration and expiration and will not cause any pain or radiation concerns. The EIT belt (3-cm diameter) will be placed around the chest without causing adverse event/discomfort/pain.
The duration of study will be approximately 30 minutes. The study will be conducted one time for one enrolled patient.
HFNC or NIV (device) failure is considered as either intubation/reintubation or death, whatever has come first. It will be followed up to 7 days.
The investigators will proceed with the measurements only with agreement from the clinical team. The investigators will analyze the data collected offline with a dedicated software afterwards.
After these study procedures are completed, data will also be collected from the participant's chart and combined with relevant information from the HFNC or NIV settings and vital functions. Confidentiality will be maintained throughout the entire study.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5B 1W8
- St. Michael's Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patient who is using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) to either prevent 1. intubation in the context of acute hypoxemic respiratory failure or 2. reintubation in the context of high risk group of extubation.
Descrição
Inclusion Criteria:
- Age of ≥ 18 years
- Using NIV or HFNC anywhere in the hospital
Exclusion Criteria:
- Chronic CO2 retention
- Neuromuscular disorder
- Requiring home NIV (CPAP or BIPAP)
- Tracheostomy
- Contraindication to EIT placement: pacemaker/defibrillator implantation, burns at the area of EIT placement
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Difference in regional ventilation distribution (%)
Prazo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diaphragm or parasternal intercostal muscle thickening fraction
Prazo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess ultrasound measurement of inspiratory muscle activity when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Rapid shallow breathing index (RSBI) in mL/breaths/min
Prazo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess non-invasive respiratory - rapid shallow breathing index (RSBI) derived from NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory drive using negative airway pressure generated during the first 100 millisecond (P0.1)
Prazo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory drive - using negative airway pressure generated during the first 100 millisecond (P0.1) in cmH2O to predict device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory effort using end-expiratory airway occlusion pressure (ΔPocc)
Prazo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory effort using end-expiratory airway occlusion pressure (ΔPocc) in cmH2O to predict device failure |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The intensive care respiratory distress observation scale (IC-RDOS)
Prazo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the level of dyspnea using intensive care respiratory distress observation scale (IC-RDOS) to predict a device failure. There is no minimum or maximum range depending on patient's heart rate, the higher score means worse outcome. When the score ≥ 2.4, it likely indicates clinically important dyspnea requiring clinical management. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The work of breathing scale
Prazo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the work of breathing scale to predict a device failure. Minimum is 3 and maximum is 12, the higher score means worse outcome. When the score > 4, it likely indicates severe respiratory distress. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Self-report of dyspnea visual analog scale (D-VAS)
Prazo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess self-report of dyspnea visual analog scale (D-VAS) to predict a device failure. Minimum is 0 and maximum is 10, the higher score means worse outcome. When the score > 3, it likely indicates dyspnea and being used for quality of palliative care unit |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Unity Health Toronto
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .